Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?

ID: ALA4732232

Journal: Eur J Med Chem

Title: Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?

Authors: Amin SA,Banerjee S,Gayen S,Jha T

Abstract: The fascinating similarity between the SARS-CoV and SARS-CoV-2, inspires scientific community to investigate deeper into the SARS-CoV proteases such as main protease (Mpro) and papain-like protease (PLpro) and their inhibitors for the discovery of SARS-CoV-2 protease inhibitors. Because of the similarity in the proteases of these two corona viruses, there is a greater chance for the previous SARS-CoV Mpro and PLpro inhibitors to provide effective results against SARS-CoV-2. In this context, the molecular fragments from the SARS-CoV protease inhibitors through the fragment-based drug design and discovery technique can be useful guidance for COVID-19 drug discovery. Here, we have focused on the structure-activity relationship studies of previous SARS-CoV protease inhibitors and discussed about crucial fragments generated from previous SARS-CoV protease inhibitors important for the lead optimization of SARS-CoV-2 protease inhibitors. This study surely offers different strategic options of lead optimization to the medicinal chemists to discover effective anti-viral agent against the devastating disease, COVID-19.

CiteXplore: 33618158

DOI: 10.1016/j.ejmech.2021.113294

Patent ID: ┄